New data could lead doctors to use Johnson & Johnson and Bayer's blood thinner Xarelto to prevent heart attacks in some patients. Earlier this month, Credit Suisse analyst Divan Vamil predicted that a successful result could increase sales of the drug by $1.5 billion in the U.S. alone.
from Forbes Real Time //www.forbes.com/sites/matthewherper/2017/08/27/new-data-could-add-1-5-billion-to-sales-of-johnson-johnsonbayer-blood-thinner/
via IFTTT
No comments:
Post a Comment